11/19/2023 0 Comments Kite pharma amsterdam![]() This unique partnership further positions us to deliver on the promise of T cell-based cancer immunotherapy for patients worldwide." "We are excited to announce a strategic collaboration with GE Global Research, a world leader in medical technologies and a company that shares our commitment to the future of T cell-based immunotherapy," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. " GE Global Research is the ideal partner to realize our vision to advance engineered T cell manufacturing to a functionally integrated and fully automated process. This collaboration brings together complementary capabilities from each company, including Kite's scientific leadership in T cell biology and manufacturing and GE Global Research's deep expertise in the design and development of innovative manufacturing applications for the biopharmaceutical industry. As a result, automated manufacturing technologies could enable more widespread availability of engineered T cell therapies. Kite and GE Global Research aim to change the paradigm of engineered T cell therapy manufacturing by accelerating the development of automation technologies that have the potential to reduce cost, improve speed, and minimize variability. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACTâ„¢) products for the treatment of cancer, and GE Global Research (NYSE:GE), the centralized research and development hub for GE, today announced that they have formed a strategic research collaboration to develop a next-generation, functionally integrated and automated manufacturing system for engineered T cell therapy. 3, 2015 (GLOBE NEWSWIRE) - Kite Pharma, Inc. Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |